NCT01848834View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

PHASE1CompletedINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

May 7, 2013

Primary Completion Date

April 26, 2016

Study Completion Date

June 30, 2020

Conditions
CancerSolid Tumor
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01848834 - Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | Biotech Hunter | Biotech Hunter